Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine. Animal studies have indicated that casein glycomacropeptide (CGMP) may help reduce disease activity in IBD patients.
Arla Foods Ingredients supplies Lacprodan® CGMP, a unique ingredient with a high content of casein glycomacropeptide, naturally produced from milk. Research suggests that Lacprodan® CGMP has strong potential as a natural IBD treatment.
Study of CGMP in IBD patient diets
In a recent human study, researchers investigated how our Lacprodan® CGMP was tolerated and accepted in patients with active ulcerative colitis (UC) and if the addition of Lacprodan® CGMP to the patient’s usual medical treatment (5’ASA) could improve the clinical course. The results show that the addition of Lacprodan® CGMP as an adjunct nutritional therapy to standard treatment was safe and well accepted by patients with active distal UC and that the disease-modifying effect of Lacprodan® CGMP-20 was similar to that of standard medical dose escalation.
Link to the publication, please click here.
Animal studies have indicated that part of the beneficial effects of CGMP can be attributed to:
- Prebiotic effect which promotes the growth of beneficial microflora
- High level of threonine is important for formation to the protective mucus layer in the gastrointestinal tract
- Pathogen decoy effect due to high sialic acid content
Products Casein glycomacropeptide